4 December 2024
Scancell Holdings
plc
("Scancell" or the "Company")
Scancell Announces Genmab
Exercises Option to a Second Commercial License
Agreement
Following on from a period
of exclusive evaluation announced in June 2024,
Genmab has exercised its option to license an anti-glycan monoclonal
antibody generated via Scancell's proprietary
GlyMab®
platform
This is the second
commercial license with Genmab where Genmab
has been granted
worldwide exclusive rights for the development and
commercialisation of novel therapeutic products for an antibody
from the Scancell Glymab® platform
Scancell is to receive an
upfront payment and potential development, regulatory- and
commercial milestone payments of up to a maximum of $630 million if
Genmab develops and commercialises products across all defined
modalities. Scancell will also receive low single-digit royalties
from Genmab on net sales of all such commercialised
products
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
today announces that Genmab (NASDAQ: GMAB), an international
biotechnology company, has exercised its option to license a
Scancell investigational anti-glycan monoclonal antibody whereby
Genmab has the exclusive right to develop and commercialise the
Scancell antibody in multiple novel therapeutic products.
Scancell will be eligible to receive upfront and
development and commercialisation milestone payments, as well as
royalties on products sold.
The Scancell anti-glycan monoclonal
antibody is a humanised antibody developed by Scancell, using its
novel anti-cancer GlyMab® platform. This is one of five monoclonal
antibodies currently in Scancell's antibody portfolio, which
provides a rich reservoir of potential products for its in-house
clinical development and further deals.
Prof Lindy Durrant, Chief Scientific Officer, Scancell,
commented: "This option exercise for
another anti-glycan monoclonal antibody from the Glymab® platform
builds on our existing relationship with Genmab. The commercial
license agreement follows an exclusive evaluation period, which
further validates that our Glymab® antibody platform can generate
novel, differentiated, highly tumour specific antibodies for
therapeutic development. We are positive about continuing to work
with Genmab and providing further updates to the market on both
agreements as they progress."
This is the second commercial
licence agreement Scancell has signed with Genmab following an
earlier agreement signed in October 2022.
-ENDS-
|
For
further information, please contact:
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Phil L'Huillier, CEO
Professor Lindy Durrant,
CSO
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Emma Earl, Freddy Crossley, Will
Goode, Mark Rogers (Corporate Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint Broker)
|
+44 (0) 20 3705 9330
|
|
David Wilson/Claes Spang/Satheesh
Nadarajah/Erland Sternby
|
|
|
ICR
Healthcare
|
|
|
Mary-Jane Elliott/ Angela Gray/
Lindsey Neville
|
+44 (0) 20 37095700
scancell@icrhealthcare.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab®
for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody® ) this includes citrullination
and homocitrullination of proteins, whereas its mAb portfolio
targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab® ) or enhances the potency of antibodies and their
ability to directly kill tumour cells (AvidiMab® ).
For further information about
Scancell, please visit: https://www.scancell.co.uk/
About GlyMab®
Scancell is building a pipeline of
differentiated anti-cancer monoclonal antibodies ('mAbs') that
target sugar motifs rather than proteins. The Company currently has
five novel mAbs in early-stage development and has the potential to
use its unique methodology to identify many more mAbs against
glycan targets in the future. All cells are covered by a dense
layer of sugar structures, called glycans, which change when a
normal cell turns into a cancer cell. These glycan motifs that are
associated with tumour malignancies can be targeted by antibodies
such as the Company's GlyMab® portfolio. A robust portfolio of
patents and applications, as well as know-how, surround the GlyMab®
platform and generated drug candidates. The GlyMab® technology is
part of Scancell's antibody portfolio, joining AvidiMab®, a
technology that can be applied to all antibodies (regardless of the
technology used to generate them) enhancing their potency and
ability to directly kill tumour cells. This announcement contains
inside information for the purposes of Article 7 of Regulation (EU)
596/2014 (MAR).